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Free radicalsReactive oxygen species (ROS) play important roles in peroxisome proliferator-activated receptor γ (PPARγ)
signaling and cell-cycle regulation. However, the PPARγ redox-signaling pathways in lung alveolar epithelial
cells remain unclear. In this study, we investigated the in vivo and in vitro effects of PPARγ activation on the
levels of lung ROS production and cell-cycle progression using C57BL/6J wild-type and Nox2 knockout mice
(n=10) after intraperitoneal injection of a selective PPARγ agonist (GW1929, 5 mg/kg body wt, daily) for
14 days. Compared to vehicle-treated mice, GW1929 increased signiﬁcantly the levels of ROS production in
wild-type lungs, and this was accompanied by signiﬁcant up-regulation of PPARγ, Nox2, PCNA, and cyclin D1
and phosphorylation of ERK1/2 and p38MAPK. These effects were absent in Nox2 knockout mice. In cultured
alveolar epithelial cells, GW1929 (5 μM for 24 h) increased ROS production and promoted cell-cycle
progression from G0/G1 into S and G2/M phases, and these effects were abolished by (1) adding a PPARγ
antagonist (BADGE, 1 μM), (2) knockdown of PPARγ using siRNA, or (3) knockout of Nox2. In conclusion,
PPARγ activation through Nox2-derived ROS promotes cell-cycle progression in normal mouse lungs and in
cultured normal alveolar epithelial cells.roxisomeproliferator-activated
E, bisphenol A diglycidyl ether;
eneiodonium; SOD, superoxide
gen-activated protein kinase;
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iﬁed Eagle medium.
license.© 2011 Elsevier Inc.Open access under CC BY license.The peroxisome proliferator-activated receptor γ (PPARγ) is one of
the three PPARs (α, γ, and β/δ), which belong to the nuclear receptor
family of ligand-activated transcription factors. When activated by
appropriate ligands, such as prostaglandins, polyunsaturated fatty acids,
and leukotrienes, the PPARs bind to cis-retinoic acid receptors to form a
heterodimer, which then binds to the speciﬁc regions on the target
genes called peroxisome proliferator hormone-responsive elements
(PPRE) to promote or inhibit gene transcription [1]. Among the PPARs,
PPARγ activation has been found to have pleiotropic beneﬁcial effects
in multiple tissues on lipid metabolism, glucose homeostasis, and cell-
cycle regulation [2]. PPARγ ligands have been used routinely for the
treatment of type 2 diabetes and are generally well tolerated. Despite
proven therapeutic beneﬁts, there are side effects,which includeweight
gain,ﬂuid retention, potential risk of cardiac failure, and carcinogenicity
[3–5].
PPARγ is expressed in almost every cell type of the human body
and plays important roles in organ development and function [2,3]. In
the lung, PPARγ has been found to play a central role in the early stageof lung development [6]. Mice deﬁcient in PPARγ developed air-space
enlargement with decreased tissue resistance and increased lung
volume [7], whereas treatment of mice with an agonist to PPARγ
protects newborn lungs from hypoxia-induced lung injury [8]. PPARγ
deﬁciency is also linked to pulmonary disorders such as asthma, lung
cancer, cystic ﬁbrosis, and inﬂammation, and PPARγ has been
suggested to be a potential therapeutic target to treat these diseases
[2]. On the other hand, chronic metabolic and hormonal disturbances
are characteristic of type 2 diabetic patients, which predisposes these
patients to the risk of lung cancer [9]. Although recently a clinical
retrospective database analysis had reported that PPARγ agonists
(thiazolidinediones) reduced lung cancer risk in diabetic patients
[10], there was no rational explanation and the mechanistic data
explaining PPARγ action in lung cancer are controversial. Despite the
fact that the majority of type 2 diabetic patients, when starting PPARγ
agonist treatment, are middle-aged without lung problems, detailed
investigation into the long-term effects of administration of exoge-
nous PPARγ agonists on the healthy lungs of middle-aged individuals
is still missing.
The lung epithelial cells also express abundantly an NADPH
oxidase (Nox) that generates low levels of ROS under physiological
conditions and contributes to the redox regulation of normal lung
function [11]. However, the activity of Nox can be up-regulated by
various stimuli such as metabolic disorders, and enhanced ROS
production contributes to the pathogenesis of lung diseases, such as
acute respiratory distress syndrome, bronchopulmonary dysplasia,
emphysema, idiopathic pulmonary ﬁbrosis, and cancer [11]. The Nox
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Among these Nox's, Nox2, also called gp91phox, requires the presence
of p22phox and regulatory subunits (p40phox, p47phox, p67phox, and
rac1) to generate O2•−. Nox2 has been found to be robustly expressed
in lung alveolar epithelial cells and involved in the regulation of
epithelial cell function [12].
Although both PPARγ and Nox2 are expressed in the alveolar
epithelial cells and play important roles in lung biology, little is known
regarding the role of PPARγ in the regulation of lung ROS production
by Nox2 or in the redox regulation of lung function. In this study, we
investigated the effect of PPARγ activation by GW1929, a high-afﬁnity
nonthiazolidinedione PPARγ activator [13], on the levels of ROS
production, Nox2 signaling, and cell-cycle progression in the lungs of
wild-type and Nox2 knockout (KO) mice, as well as in cultured
alveolar epithelial cells isolated from these mice.Materials and methods
Reagents
Dihydroethidium (DHE) was purchased from Molecular Probes
(UK). The polyclonal antibodies against p22phox, Nox2, Nox4, and α-
tubulin were from Santa Cruz Biotechnology; antibodies to phospho-
ERK1/2, phospho-p38MAPK, phospho-JNK, proliferating cell nuclear
antigen (PCNA), and cyclin D1 were from Cell Signaling Technology.
Polyethyleneimine (linear MW 25,000) was from Polysciences (UK).
GW1929 and other reagents and chemicals were from Sigma unless
stated otherwise.Animals and GW1929 treatment.
Wild-type and Nox2 KO mice on the C57BL/6 background (The
Jackson Laboratory) were bred in our institution from heterozygous
mice and genotyped. All studies were performed in accordance with
protocols approved by the Home Ofﬁce under the Animals (Scientiﬁc
Procedures) Act 1986 UK. Animals were housed under standard
conditions with a 12-h light and dark cycle and fed a normal chow
diet. Middle-aged male mice (6–7 months of age, n=10–12/per
group) were injected intraperitoneally once daily with either vehicle
(4% dimethyl sulfoxide (DMSO)/phosphate-buffered saline (PBS)) or
GW1929 (5 mg/kg body wt in 4% DMSO/PBS). The dose was chosen
based on previous publications [13,14]. Measurements of blood
pressure before and after treatment were obtained using computerized
tail-cuff plethysmography in conscious mice after 5 days of training
periods. On day 14, the levels of fasting glucose were taken and the
levels of fasting serum insulin were measured using a mouse insulin
ELISA kit (Mercodia Developing Diagnostic, Sweden). Mice were killed
and body weights were obtained. Tissues were harvested, washed, and
snap-frozen for further experiments.Cell culture
Pulmonary alveolar epithelial cells of wild-type and Nox2 KOmice
were obtained by primary explant culture. Brieﬂy, blocks of
pulmonary alveolar tissues (2 mm3 in dimension) of untreated
animals were seeded onto cell culture dishes and incubated at 37 °C,
5% CO2, in 10% fetal calf serum (FCS)/DMEM. After 2 weeks of culture,
outgrowing alveolar epithelial cells were characterized by ﬂow
cytometry. Cells were counted and reseeded at 1×106/100-mm2
dish and cultured for 24 h to reach 95% conﬂuence. Cells were then
treated with either vehicle (0.125% DMSO) or GW1929 (5 μM) or
bisphenol A diglycidyl ether (BADGE; 1 μM) in culture medium for
48 h before being harvested and used for further analysis.Measurement of ROS production
Tissue homogenates were prepared as described previously
[15]. O2•− production by tissue homogenates was measured by
lucigenin chemiluminescence (Lumistar; BMG) as described previ-
ously [15]. The speciﬁcity of O2•− thus measured was conﬁrmed by
adding tiron (10 mM), a nonenzymatic scavenger of O2•−. The
enzymatic sources of O2•− production were identiﬁed by preincuba-
tion of tissue homogenates with inhibitors targeting nitric oxide
synthase (Nω-nitro-L-arginine methyl ester (L-NAME), 100 μM), the
mitochondrial electron transport chain (rotenone, 50 μM), xanthine
oxidase (oxypurinol, 250 μM), ﬂavo-proteins (diphenyleneiodonium
(DPI), 20 μM), and Nox (apocynin, 20 μM). The effect of Cu/Zn
superoxide dismutase (SOD) on ROS production was investigated by
preincubation (30 min) of tissue homogenates with a speciﬁc
inhibitor, diethyldithiocarbamate (DDC; 200 μM) before O2•− mea-
surement. ROS generation within the lung tissues in situ was also
measured using DHE ﬂuorescence as described previously [16].
Fluorescence intensity was acquired using a Zeiss LS510 confocal
microscopy system and quantiﬁed from at least three random ﬁelds
(269.7×269.2 μm) per slide, three slides per animal, and six animals
per group.
Immunoblotting
Soluble protein concentrations of the lung homogenate were
determined by using a Bio-Rad kit (Bio-Rad Laboratories, UK).
Immunoblotting using 40 μg protein per lane was performed as
described previously [16]. The images were captured digitally using a
BioSpectrum AC imaging system (UVP, UK), and the densities of the
protein bands were normalized to the loading control bands and
quantiﬁed. The results were expressed as the means±SD of six
animals.
Immunoﬂuorescence microscopy
Sample preparation and confocal microscopy were performed as
described previously [16]. Brieﬂy, frozen sections (6 μm) were ﬁrstly
treated with a biotin blocking kit (DAKO) according to the manufac-
turer's instructions. Primary antibodies were used at a 1:250 dilution
in PBS with 0.1% bovine serum albumin for 30 min at room
temperature. Biotin-conjugated anti-rabbit or anti-goat (1:1000
dilution) antibodies were used as secondary antibodies. Speciﬁc
binding was detected by extravidin–FITC or streptavidin–Cy3. Normal
rabbit or goat IgG (5 μg/ml) was used instead of primary antibody as a
negative control. Images were acquired on an Olympus BX61
ﬂuorescence microscopy system and stored digitally for analysis.
Fluorescence intensities of samples acquired under the same
microscopic parameter were quantiﬁed from at least three random
ﬁelds (433×330 μm) per slide, three slides per animal, and six
animals per group.
PPARγ or Nox2 small interfering RNA (siRNA) transfection
Primary pulmonary alveolar epithelial cells were plated (5×105
cells/well) in six-well plates in 10% FCS/DMEM. Mouse PPARγ siRNA
and a random scrambled control siRNA were from Santa Cruz
Biotechnology (sc-29456). The nucleotide sequences of Nox2 siRNA
and a random negative control siRNA were as described previously
[16]. The gene transfection was performed as described previously
[16], with somemodiﬁcation. Brieﬂy, 3 μg siRNAwasmixedwith 30 μl
polyethyleneimine (concentration 1 mg/ml) and then diluted in
300 μl of serum-free DMEM. The transfection mixture was incubated
at room temperature for 15 min. Cells were washed and the medium
was replaced with 1.2 ml serum-free DMEMper well. The transfection
mixture (300 μl) was added into the cell culture to make up to 1.5 ml/
Table 1
Blood pressure and metabolic measurements.
Measure Wild-type Nox2 knockout
Vehicle GW1929 Vehicle GW1929
Body weight (g) 40.7±0.8 42.6±2.0 40.2±4.2 38.3±3.1
Systolic blood pressure
(mm Hg)
140.7±11.4 146.3±15.7 139.2±14.0 145.6±16.3
Diastolic blood pressure
(mm Hg)
110.8±7.0 121.0±13.0 113.5±9.7 119.6±19.5
Serum insulin (μg/L) 1.048±0.67 1.122±0.66 0.998±0.98 0.745±0.42
Fasting blood glucose
(mM)
6.54±0.45 6.07±0.55 5.33±0.40 5.57±1.1
765J. Tickner et al. / Free Radical Biology & Medicine 51 (2011) 763–772well. Cells were incubated for 4 h before 1.5 ml of 20% FCS/DMEMwas
added into the well. Cells were cultured continually overnight. The
next morning, the medium was replaced with fresh 10% FCS/DMEM.
After 24 h of culture, cells were treated with either vehicle or 5 μM
GW1929 for 48 h as described above.
Cell cycle analysis
After 48 h of treatment with vehicle or GW1929, the cells were
detached with trypsin/EDTA, counted, and used immediately for cell-
cycle analysis as described previously [17]. Brieﬂy, the cells were ﬁxedHeart
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Fig. 1. The effects of in vivo treatment with GW1929 on NADPH-dependent O2•− production
indicated values versus vehicle values in the same organ.with 70% ethanol, treated with RNase A (0.2 mg/ml), and then stained
with propidium iodide (50 μg/ml) for DNA content. The number of
cells in G0/G1, S, and G2/M phases and of apoptotic cells was counted
using an Accuri C6 ﬂow cytometer and analyzed using the Cﬂow
program.
Statistical analysis
Data are presented as means±SD of the results from 10–12 mice
per group for the in vivo experiments, and from at least three
independent cell isolations for the in vitro experiments. Comparisons
weremade by unpaired Student's t test, with Bonferroni correction for
multiple testing. Pb0.05 was considered statistically signiﬁcant.
Results
The effects of GW1929 on lung ROS production
Compared to vehicle-treated controls, treatment of both wild-type
and Nox2 KO mice (6–7 months of age) with GW1929 (5 mg/kg body
wt, daily) for 14 days had no signiﬁcant effect on the body weight,
blood pressure, fasting blood glucose, and insulin levels (Table 1). We
then examined the potential effects of systemic administration of
GW1929 on NADPH-dependent O2•− production in various organs ofBrain
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There was no signiﬁcant difference in the levels of O2•− production in
the hearts, skeletal muscles, aortas, brains, or livers between mice
treated with GW1929 and those treated with vehicle. However, there
was an ~2.5-fold increase in the levels of O2•− production in the lungs
of GW1929-treated mice compared to vehicle-treated controls.
The effect of GW1929 on wild-type lung ROS production was
further examined in detail (Fig. 2). In the absence of NADPH, the basic
levels of lung O2•− production were very low and there was no
signiﬁcant difference between vehicle- and GW1929-treated groups.
However, when NADPHwas added, there were signiﬁcant increases in
the levels of O2•− production by GW1929-treated lungs compared to
vehicle-treated controls (Fig. 2A, left). Increased NADPH-dependent
O2•− production found in GW1929-treated lungs was not due to theM
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values under the same conditions. Scale bar=50 μm.changes in the expression and activity of the extracellular Cu/Zn SOD,
because preincubation of lung homogenates with a Cu/Zn SOD
inhibitor, DDC (200 μM), for 30 min had no signiﬁcant effect on the
levels of ROS production compared to samples without DDC
pretreatment (Fig. 2A, right). GW1929-induced increase in O2•−
production was inhibited by apocynin (a Nox inhibitor) or DPI (a
ﬂavo-protein inhibitor), but not by L-NAME (NOS inhibitor), oxypur-
inol (xanthine oxidase inhibitor), or rotenone (mitochondrial com-
plex 1 enzyme inhibitor) (Fig. 2B). Tiron, a speciﬁc O2•− scavenger, was
used to conﬁrm the detection of O2•− by chemiluminescence. The
GW1929-induced lung ROS production was further examined in situ
by DHE ﬂuorescence on lung sections (Fig. 2C). Signiﬁcant increases in
DHE ﬂuorescence were observed in GW1929-treated lungs compared
to the vehicle controls. Moreover, the GW1929 effect was signiﬁcantly7 40
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that Nox might be responsible for increased lung O2•− production after
GW1929 treatment.
We then treated the Nox2 KO mice with GW1929 for 14 days and
measured the NADPH-dependent lung O2•− production exactly as we
did for the wild-type mice. Compared to vehicle-treated wild-type
mice, GW1929 treatment had no signiﬁcant effect on the levels of O2•−
production by Nox2 KO lungs as examined by lucigenin chemilumi-
nescence (Fig. 3A) or by DHE ﬂuorescence (Fig. 3B).
The effects of GW1929 on lung expression of PPARγ and Nox
The results of lung O2•− production strongly suggested an
involvement of Nox2 enzyme; we therefore examined the levels of
protein expression of PPARγ, Nox2, Nox4, and p22phox in the wild-
type lungs byWestern blotting (Fig. 4A). Compared to vehicle-treated
controls, GW1929 increased signiﬁcantly the protein expression of
PPARγ and Nox2, and this was coupled to a decrease in Nox4
expression. There was no signiﬁcant change in the levels of p22phox
expression. The increases in the expression of PPARγ (FITC, green)
and Nox2 (Cy3, red) were further conﬁrmed by immunoﬂuorescence
(Fig. 4B). There was no signiﬁcant difference in the numbers of CD45+
cells (Cy3, red) between vehicle- and GW1929-treated lung sections
as counted against the total cell nuclei labeled with DAPI (blue).
Parallel sectionswere stainedwith hematoxylin and eosin to show the
lung morphology.
GW1929-induced MAPK activation and cell-cycle molecule expression in
the lungs
The mitogen-activated protein kinases (MARKs) have been
reported to be redox sensitive and involved in Nox2 signaling [16].
MAPKs are also important downstream signaling molecules of PPARγ
[18]. To ﬁnd out whether MAPKs are involved in bridging PPARγ and
Nox2 signaling, we examined the phosphorylation of ERK1/2,
p38MAPK, and JNK in the wild-type lungs by immunoblotting using
phosphorylation-speciﬁc monoclonal antibodies (Fig. 5A). There was
no signiﬁcant change in the expression of total ERK1/2 and p38MAPK0
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Fig. 3. The effects of in vivo treatment with GW1929 on ROS production by Nox2 KO
lungs. (A) NADPH-dependent lucigenin chemiluminescence. (B) DHE ﬂuorescence;
tiron was used to conﬁrm the detection of O2•−.between vehicle- and GW1929-treated groups. However, there were
signiﬁcant increases in the levels of ERK1/2 and p38MAPK phosphor-
ylation in the GW1929-treated group compared to vehicle-treated
controls. The levels of JNK expression were very low without a
signiﬁcant difference between vehicle- and GW1929-treated groups.
Since MAPKs are upstream signaling molecules involved in cell-
cycle regulation, we examined also the levels of expression of PCNA
and cyclin D1, two of the critical molecules required for cell
proliferation and cell-cycle progression from G0/G1 phase to S
phase. We found that GW1929 treatment increased signiﬁcantly the
protein expression of PCNA and cyclin D1 in the wild-type lungs
compared to vehicle-treated controls (Fig. 5A). The levels ofα-tubulin
in the same samples were used as loading controls. Immunoﬂuores-
cence double staining of lung sections with PCNA (red) plus
cytokeratin (epithelial cell marker, green) or CD31 (endothelial cell
marker, green) indicated that increased expression of PCNAwas in the
alveolar epithelial cells (Fig. 5B).
We then examined the expression of PPARγ, Nox4, PCNA, and
cyclin D1 and the phosphorylation of ERK1/2 in the Nox2 KO lungs
treated with vehicle or GW1929 (Fig. 5C). We found that GW1929
treatment increased signiﬁcantly the lung expression of PPARγ in
Nox2 KO mice. However, in the absence of Nox2, GW1929 had no
signiﬁcant effect on the levels of expressions of Nox4, PCNA, and
cyclin D1. Similarly, there was no signiﬁcant difference in the levels of
ERK1/2 phosphorylation between vehicle- and GW1929-treated
lungs. The levels of expression of α-tubulin in the same samples
were used as loading controls.
GW1929-induced ROS production and cell-cycle progression in alveolar
epithelial cells
To ﬁnd out if the effects of GW1929 on lung ROS production and
cell-cycle progression were indeed on alveolar epithelial cells, we
isolated alveolar epithelial cells by primary explant culture. The purity
of the alveolar epithelial cells was conﬁrmed, as they are ~95%
positive for cytokeratin (an epithelial cell marker) and negative for
CD31 and CD45 as detected by ﬂow cytometry (Supplementary Fig. 2).
There were ~11% of cells positive for vimentin (a ﬁbroblast marker),
which is well known to be weakly expressed by proliferating
epithelial cells in culture. Cells were exposed either to vehicle or to
GW1929 (5 μM) for 48 h in the presence or absence of a known PPARγ
antagonist, BADGE (1 μM) [19], and examined for NADPH-dependent
O2•− production and cell-cycle progression (Fig. 6A). Compared to the
vehicle controls, treatment of cells with GW1929 signiﬁcantly
increased the levels of O2•− production (Fig. 6A, left) and promoted
cell-cycle progression from G0/G1 phase to S and G2/M phase, i.e., the
cell numbers in G0/G1 phase were signiﬁcantly reduced, and those in
S and G2/M phases were signiﬁcantly increased (Fig. 6A, right).
Blockade of PPARγ with BADGE reduced slightly but signiﬁcantly the
levels of ROS production without a signiﬁcant effect on cell-cycle
progression. However, when PPARγ was blocked by BADGE, treat-
ment of cells with GW1929 reduced signiﬁcantly the levels of ROS
production, which was accompanied by cell detachment and death.
Within the remaining adherent cells, ~30% were apoptotic (Fig. 6A,
right).
The critical role of PPARγ in promoting alveolar epithelial cell ROS
production and cell-cycle progression was further examined by
knockdown of PPARγ using siRNA (Fig. 6B). The transfection
efﬁciency was conﬁrmed by Western blot (Fig. 6B, left bottom). In
cells transfected with scrambled control siRNAs, GW1929 treatment
signiﬁcantly increased the O2•− production (Fig. 6B, left) and promoted
cell-cycle progression from G0/G1 phase into S and G2/M phases
(Fig. 6B, right) compared to vehicle-treated control cells. Knockdown
of PPARγ signiﬁcantly decreased the levels of ROS production in
vehicle-treated cells without signiﬁcant effect on cell-cycle progres-
sion. However, when PPARγ was knocked down, GW1929 treatment
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768 J. Tickner et al. / Free Radical Biology & Medicine 51 (2011) 763–772failed to increase ROS production by cells, and this was accompanied
by cell detachment and death. In the remaining adherent cells, ~20%
were apoptotic (Fig. 6B, right).
The effects of Nox2 siRNA or Nox2 knockout on GW1929-induced lung
ROS production and cell-cycle progression
To conﬁrm that Nox2 was indeed responsible for GW1929-
induced O2•− production by alveolar epithelial cells, we transfected
wild-type cells with Nox2 siRNA and examined the levels of NADPH-
dependent O2•− production (Fig. 7A). In cells transfected with
scrambled control siRNAs, GW1929 treatment signiﬁcantly increased
the ROS production. However, in cells transfected with Nox2 siRNA,
GW1929 had no signiﬁcant effect on cell O2•− production. Finally, the
critical roles of Nox2 in GW1929-induced O2•− production and cell-
cycle progression were conﬁrmed using alveolar epithelial cells
isolated from Nox2 KO mice (Fig. 7B). We found that Nox2 KO cells
had a very low level of NADPH-dependent O2•− production comparedto wild-type cells (shown in Fig. 6A) and GW1929 treatment had no
signiﬁcant effect on the levels of O2•− production by these cells.
Accordingly, there was no signiﬁcant difference in cell-cycle proﬁles
between vehicle-treated and GW1929-treated Nox2 KO cells (Fig. 7B,
right).
Discussion
It is well known that PPARγ has a wide range of actions on glucose
homeostasis and metabolism, and many exogenous PPARγ agonists
have been used to treat type 2 diabetes and insulin resistance.
However, PPARγ hasmany other actions on cellular biology, including
cell proliferation, differentiation, and apoptosis, which may cause
therapeutic complications such as ﬂuid retention, cardiac hypertrophy
and failure, andpotential carcinogenicity [3]. The carcinogenicity issue is
controversial because of discrepancies between studies. For example,
most studies reported that PPARγ activation inhibited cancer cell
proliferation and tumor growth, whereas others found that PPARγ
A) Wild-type Western blots
p-ERK1/2
0
10
20
30
40 *
Ar
bi
tra
ry
 u
ni
ts
p-p38MAPK
0
10
20
30
*
Cyclin D1
*
PCNA
Ar
bi
tra
ry
 u
ni
ts
0
20
40
60 *
Vehicle GW1929 Vehicle GW1929
T-p38MAPK
p-p38MAPK
p-ERK1/2
T-ERK1/2
p-JNK
T-JNK
Cyclin D1
α-tubulin
PCNA
Vehicle GW1929
C) Nox2 KO Western blots 
Nox4
0
20
40
60
80
PCNA
Vehicle GW1929 Vehicle GW1929
0
10
20
30
Ar
bi
tra
ry
 U
ni
ts p-ERK1/2
0
10
20
30
Cyclin D1
0
10
20
30
PPARγ
0
20
40
60
Ar
bi
tra
ry
 U
ni
ts *
Ar
bi
tra
ry
 U
ni
ts
P-ERK1/2
Nox4
T-ERK1/2
PPARγ
Cyclin D1
PCNA
α-tubulin
Vehicle GW1929
B) Wild-type Immunofluorescence
PCNA (red) +
Cytokeratin
PCNA (red)
+ CD31
Vehicle GW1929
Fig. 5.MAPK phosphorylation and the expression of PCNA and cyclin D1 in the lung tissues. (A) Western blots of lung homogenates. (B) Immunoﬂuorescence of lung sections. PCNA
was labeled by Cy3 (red) and cytokeratin or CD31 was labeled by FITC (green). (C)Western blots of Nox2 KO lung homogenates. The levels of the protein bands detected byWestern
blot were quantiﬁed and normalized to the levels of α-tubulin detected in the same sample. *Pb0.05 for indicated values versus vehicle values in the same graph.
769J. Tickner et al. / Free Radical Biology & Medicine 51 (2011) 763–772
AB
ROS production
C
o
u
n
t
Vehicle
Apo S
G2/M
G0/G1 GW1929
GW1929
+BADGE
Vehicle
GW1929
0
400
800
1200
1600
Control +BADGE
*
†
†
M
L
U
/
0
.
1
 
m
g
 
p
r
o
t
e
i
n
0
400
800
1200
1600
M
L
U
/
0
.
1
 
m
g
 
p
r
o
t
e
i
n
FL2-A
C
o
u
n
t
0 200 400 500
FL2-A
0 200 400 500
Vehicle
+BADGE
8
0
0
2
0
0
4
0
0
6
0
0
0
Control
siRNA GW1929
PPARγ
siRNA
C
o
u
n
t
0 250 500
GW1929
C
o
u
n
t
0 250 500
8
0
0
2
0
0
4
0
0
6
0
0
0
VehicleControl
siRNA
PPARγ
siRNA
*
†
†
Vehicle
GW1929
%
 
o
f
 
t
o
t
a
l
 
c
e
l
l
s
Cell cycle analysis
Vehicle
8
0
0
2
0
0
4
0
0
6
0
0
0
8
0
0
2
0
0
4
0
0
6
0
0
0
%
 
 
o
f
 
 
t
o
t
a
l
 
c
e
l
l
s
0
30
60
90
G0/G1 S G2/M Apo
*
*
*
*
*
0
30
60
90
G0/G1 S G2/M Apo
Vehicle
GW1929
BADGE
BADGE+GW1929
Vehicle
GW1929
Vehicle
Control siRNA
GW1929 PPARγ siRNA
*
*
*
*
*
ROS production
PPARγ
α-tubulin
Cell cycle analysis
Fig. 6. ROS production and cell-cycle analysis of isolated alveolar epithelial cells fromwild-type mice. (A) The effects of PPARγ blockade by BADGE. (B) The effects of PPARγ knockdown by siRNA. Transfection efﬁciency was shown byWestern
blot. Left: NADPH-dependent O2•− production detected by lucigenin chemiluminescence. *Pb0.05 for indicated values versus vehicle control values. †Pb0.05 for indicated values versus control values in the same treatment group. Right: Flow
cytometry. *Pb0.05 for indicated values versus vehicle values in the same cell-cycle phase.
770
J.Tickner
et
al./
Free
Radical
Biology
&
M
edicine
51
(2011)
763
–772
A) WT cells
Cell cycle analysis
20
0
40
0
60
0
80
0
0
co
u
n
t
Vehicle
20
0
40
0
60
0
80
0
0
0 200 400 500
FL2-A
GW1929
co
u
n
t
ROS production
0
50
100
150
Control
siRNA
Nox2
siRNA
%
 o
f v
eh
icl
e 
co
nt
ro
l
Vehicle
GW1929*
ROS production
0
4000
8000
12000
16000
1 4 7 10 13 16 19
Minutes
Li
gh
t u
ni
ts
/0
.1
 m
g 
pr
ot
ei
n Vehicle
GW1929
B) Nox2 KO cells
Fig. 7. The effects of Nox2 siRNA or Nox2 KO on alveolar cell O2•− production and cell-cycle progression. (A) Wild-type alveolar epithelial cells. (B) Nox2 KO alveolar epithelial cells.
NADPH-dependent O2•− production was measured by lucigenin chemiluminescence. Cell cycle progression was measured by ﬂow cytometry. *Pb0.05 for indicated values versus
control vehicle values; n=3 independent cell isolations.
771J. Tickner et al. / Free Radical Biology & Medicine 51 (2011) 763–772activation potentiates tumorigenesis [20]. Different types of tissues
respond differently to PPARγ activation and the mechanistic data are
still missing to explain the mode of its involvement in tumor
development. In this study we report, for the ﬁrst time, that PPARγ
activation through Nox2-derived ROS promotes cell-cycle progression
in normal mouse lungs. We showed clearly, using middle-aged wild-
typeandNox2KOmice, that systemic administrationof a speciﬁc PPARγ
agonist (GW1929) increased theROSproduction fromtheNox2enzyme
speciﬁcally in the lung, and not in theheart, skeletalmuscle, aorta, brain,
or liver. Increased ROS levels were associated with increases in MAPK
activation and the expression of PCNA and cyclin D1, two of the most
important modulators directly involved in cell proliferation and cell-
cycle progression. These effects were mainly due to PPARγ actions on
alveolar epithelial cells as demonstrated by experiments using primary
alveolar epithelial cells isolated from thewild-typemice and conﬁrmed
byblockadeof PPARγwithBADGE (an identiﬁedPPARγ antagonist) [19]
or knockdown of PPARγ using siRNA.
ROS have multiple effects on cellular function depending on the
amount and subcellular location of the ROS generated. The cell cycle
has been proposed to be a redox cycle [21]. Physiological changes in
intracellular ROS levels are critical for cellular signaling and survival.
However, prolonged oxidative stress or lack of oxidative stimulation
causes cell apoptosis and death. In this study, we found that increased
ROS production by Nox2 in response to PPARγ activation by GW1929
induced PCNA and cyclin D1 expression and promoted primary
alveolar epithelial cell-cycle progression from G1 into S and G2/M
phase. However, when ROS levels were low because of PPARγblockade by BADGE or knockdown by siRNA, the cell cycle arrested.
Moreover, when PPARγ was not available, GW1929 failed to increase
cellular ROS production and caused cell death.
The mitogenic effects of ROS involve the modulation of redox-
sensitive signaling molecules such as the MAPK superfamily, which
lead to the activation of transcriptional factors and cell-cycle
molecules, i.e., cyclins and cyclin-dependent kinases. MAPKs, in
particular ERK1/2, have been shown to be involved in mediating
PPARγ action in mousemyoblast cells and lung carcinoma cells [1,22].
In accordance with these previous reports, we found that PPARγ
activation led to ERK1/2 and p38MAPK activation in the lung of
normal mice, but not in the Nox2 knockout mice. Moreover, we found
that PCNA and cyclin D1 were the downstream cell-cycle targets of
ROS generated by Nox2 in response to PPARγ activation.
Cell cycle progression is tightly controlled by interactions between
cyclins and cyclin-dependent kinases, and many of these cell-cycle
molecules, such as cyclin D1, contain redox-sensitive cysteine residues
and respond to the ﬂuctuations in intracellular redox status that are
linked to cell metabolism [21]. Nox2 has been found to be expressed
constitutively in alveolar epithelial cells and plays important roles in the
regulation of normal lung function and is involved in thepathogenesis of
many lung diseases [11]. Previously, we have reported a critical role for
O2•− generated by Nox2 in cell-cycle regulation in endothelial cells [23].
In the current study,we found thatNox2 is involved inmediating PPARγ
signaling in the lungs. Increases in O2•− levels in response to PPARγ
activation were not due to the changes in lung Cu/Zn SOD activity
because inhibition of Cu/Zn SOD with or without a speciﬁc inhibitor,
772 J. Tickner et al. / Free Radical Biology & Medicine 51 (2011) 763–772DDC, had no signiﬁcant effect on the proportions of GW1929-
induced ROS production in these samples [24]. Furthermore, the
critical roles of Nox2-derived ROS in mediating PPARγ signaling
were conﬁrmed by (1) knocking down Nox2 using siRNA, (2) using
cells isolated from Nox2 knockout mice, and (3) treating Nox2
knockout mice with GW1929. In these cases, GW1929 failed to
increase ROS production or to promote cell-cycle progression. A
putative PPRE (motif TGACCT) can be found in the Nox1 and Nox2
promoter regions. Interestingly, the PPRE in the Nox2 promoter is
in an antisense orientation and is next to another PPRE-related
motif (TGAAC) [25]. Further detailed investigation of PPARγ
transcriptional regulation of Nox2 is required for understanding
the mechanism.
It is also well documented that alveolar epithelial cells express
Duox (Duox1 and Duox2), which generates mainly H2O2 in response
to microorganism invasion or during epithelial differentiation [11].
However, different from Nox, Duox contains Ca2+-binding domains
and its activation requires Ca2+ mobilization [11]. Therefore, Duox is
unlikely to be the major source of PPARγ activation-induced O2•−
production in the lungs.
Although there is no evidence directly linking long-term PPARγ
activation to lung cancer, patients suffering from type 2 diabetes have
been found to have an elevated risk of cancer development, including
lung carcinomas, regardless of their therapy [9]. PPARγ expression is
highly up-regulated in lung cancers and has been suggested as a
potential marker for lung cancer [26]. It is well known that PPARγ
ligands have distinct activities between different cell types, between
tumor cells derived from the same tissue, and between different
tissues [1,3]. Cell proliferation and cell-cycle progression induced by
thiazolidinediones (PPARγ agonists) have been reported in normal
human bronchial epithelial cells [27], and speciﬁc knockout of PPARγ
in the lung epithelium affected the postnatal lung development such
that the mice had enlarged lung air spaces and decreased lung tissue
resistance [7]. A PPARγ agonist has been found to increase lung
angiogenesis [8]. It is therefore possible that long-term administration
of PPARγ agonists may compromise pulmonary epithelial cell
function and cell-cycle regulation [27].
There is controversy in the literature regarding the effects of
PPARγ activation on lung epithelial cells depending on the type of
cells used for the studies. Most previous studies were carried out on
lung carcinoma cells or immortalized cell lines, or in animal models of
growing lung cancers, and described PPARγ agonists as inhibitors of
lung oxidative stress and cell-cycle progression [1,22]. However,
mechanistic information and redox-signaling pathways of PPARγ in
normal alveolar epithelial cells are still missing. In this study, we
found that PPARγ activation by GW1929 promoted primary alveolar
epithelial cell ROS production by Nox2 and cell-cycle progression. The
discrepancy between ours and most previous studies might rest on
the fundamental differences between healthy lungs and lung
carcinomas and between primary normal alveolar epithelial cells
and cancerous cells. On the other hand, the lung is at high risk for
oxidative stress, as it interacts with various airborne oxidants.
Therefore, PPARγ activation-induced Nox2 activation and ROS
productionmay also represent a mechanism of adaption or protection
from a diverse range of internal and external stimuli, which may be a
beneﬁcial response. Further investigation is needed to determine the
role of PPARγ in the development of lung diseases.
In conclusion, we have reported for the ﬁrst time that PPARγ is
involved in the regulation of lungROSproductionbyNox2and the redox
regulation of cell-cycle progression. PPARγ activation induces Nox2-
dependent ROSproduction,which results inMAPK activation, PCNAand
cyclin D1 up-regulation, and cell-cycle progression in alveolar epithelial
cells. The mechanistic data from our study provide insights into PPARγ
redox signaling and its effects on lung pathophysiology.
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at doi:10.1016/j.freeradbiomed.2011.05.027.Acknowledgment
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